Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option. The phase 3 PROTEUS trial data may add a new ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

Johnson & Johnson (JNJ) reported late-stage clinical trial results showing that adding its prostate cancer drug apalutamide to hormone therapy before and after surgery improved outcomes for men with ...

Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product ...

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status. This is an ASCO Meeting Abstract from the 2024 ASCO ...

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. An updated analysis of patients in the SPARTAN ...

In this study, researchers aimed to determine whether adding apalutamide to ADT improves outcomes in high-risk prostate cancer compared to placebo plus ADT. Apalutamide was associated with a ...